tirzepatide nash phase 3 Nearly 62% achieve MASH resolution without worsening of fibrosis with Tirzepatide for Non-alcoholic Fatty Liver

Semaglutide users tend to experience more pronounced appetite suppression, which can lead to greater reductions in overall food intake and therefore larger nutritional gaps

Therefore, we conducted a target trial emulation using de-identified electronic health record (EHR) data from Optum Labs Data Warehouse (OLDW) to evaluate the long-term effectiveness and safety of GLP-1RA initiation in T1D

10.1038/s41571-020-00462-0 6 ChengQ.LiuY

Stanford suspects it may be tied to a shift in sensory focus as GLP-1 users experience reduced food reward

It is important to continue to feed the body even while on a metabolic support plan